MBRX · Moleculin Biotech, Inc.
AI read · Good for MBRX
The AI's read
That protection gives Moleculin another way to protect how Annamycin is prepared in a key market. Its wider patent portfolio may help with future sales or partnerships. But this news gives no patient results or drug approval, so it strengthens legal protection without showing the drug works.